Literature DB >> 28458786

Large Plasmacytoma Occupying the Upper Limb in a Myeloma Patient.

Junichiro Takano1, Kensuke Ohikata2, Daisuke Nagase3, Toru Igari2, Kazuhiko Natori3, Shotaro Hagiwara1.   

Abstract

Extramedullary disease (EMD) is an issue for patients with multiple myeloma (MM), since extramedullary spread of MM is associated with an aggressive course and a poor prognosis. Moreover, the mechanism of EMD development is uncertain. Here, we present extensive extramedullary plasmacytoma occupying the left upper limb of a 66-year-old female patient with MM with an extremely aggressive course and multiple visceral organ involvement without bone marrow infiltration or plasma cell leukemia. EMD of this large size is extremely rare and this case may provide a clue for better understanding of clinical features of EMD in MM.

Entities:  

Keywords:  Extramedullary diseases; Multiple myeloma; Tumor heterogeneity

Year:  2017        PMID: 28458786      PMCID: PMC5391517          DOI: 10.4081/rt.2017.5866

Source DB:  PubMed          Journal:  Rare Tumors        ISSN: 2036-3605


  16 in total

1.  Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients.

Authors:  Florence Magrangeas; Hervé Avet-Loiseau; Nikhil C Munshi; Stéphane Minvielle
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

2.  Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis.

Authors:  Marcus Kremer; German Ott; Michaela Nathrath; Katja Specht; Katrin Stecker; Christoph Alexiou; Leticia Quintanilla-Martinez; Falko Fend
Journal:  J Pathol       Date:  2005-01       Impact factor: 7.996

Review 3.  Clonal evolution in cancer.

Authors:  Mel Greaves; Carlo C Maley
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

4.  Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.

Authors:  K Noborio-Hatano; J Kikuchi; M Takatoku; R Shimizu; T Wada; M Ueda; M Nobuyoshi; I Oh; K Sato; T Suzuki; K Ozaki; M Mori; T Nagai; K Muroi; Y Kano; Y Furukawa; K Ozawa
Journal:  Oncogene       Date:  2008-10-13       Impact factor: 9.867

5.  Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma.

Authors:  Cyrus V Hedvat; Raymond L Comenzo; Julie Teruya-Feldstein; Adam B Olshen; Scott A Ely; Keren Osman; Yana Zhang; Nagesh Kalakonda; Stephen D Nimer
Journal:  Br J Haematol       Date:  2003-09       Impact factor: 6.998

6.  p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma.

Authors:  Neil Sheth; Joanna Yeung; Hong Chang
Journal:  Leuk Res       Date:  2009-02-08       Impact factor: 3.156

Review 7.  Unravelling cancer stem cell potential.

Authors:  Benjamin Beck; Cédric Blanpain
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

8.  Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients.

Authors:  Adriana Morgan Oliveira; Durvanei Augusto Maria; Martin Metzger; Camila Linardi; Ricardo Rodrigues Giorgi; Fernanda Moura; Gracia Aparecida Martinez; Sérgio Paulo Bydlowski; Estela Maria Novak
Journal:  Leuk Res       Date:  2008-10-30       Impact factor: 3.156

9.  High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma.

Authors:  B Barlogie; L Smallwood; T Smith; R Alexanian
Journal:  Ann Intern Med       Date:  1989-04-01       Impact factor: 25.391

10.  Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma.

Authors:  Athanasios B-T Fassas; Tray Spencer; Jeffrey Sawyer; Maurizio Zangari; Choon-Kee Lee; Elias Anaissie; Firas Muwalla; Christopher Morris; Bart Barlogie; Guido Tricot
Journal:  Br J Haematol       Date:  2002-09       Impact factor: 6.998

View more
  1 in total

1.  Late-stage myeloma invades kidney without significant effect on renal function: findings from 53 autopsies in a single institute.

Authors:  Junichiro Takano; Sohtaro Mine; Makoto Mochizuki; Noriko Tanaka; Shotaro Hagiwara
Journal:  Int J Hematol       Date:  2018-10-16       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.